
Regencell Bioscience Investors Face Class Action After DOJ Probe
Institutional investors holding Regencell Bioscience shares between October 2024 and October 2025 face a critical window to join a pending securities class action. The lawsuit follows a massive valuation swing and a federal investigation into trading activities that left fiduciaries questioning their portfolio oversight and due diligence obligations.


























